Research press release


Nature Medicine

Curtailing cancer-induced epilepsy



H Sontheimerたちは、米食品医薬品局が認可しているスルファサラジンというシスチン/グルタミン酸輸送体阻害剤を、腫瘍をもつマウスに投与した。この薬は、現在は消化管に炎症のある患者の治療に使われているが、これが脳のグルタミン酸レベルの腫瘍による上昇を防ぎ、マウスの神経膠腫誘発性てんかんの発作を減少させることが明らかになった。この知見は、ヒトの脳腫瘍が誘発するてんかん発作を減少させる新しい治療法につながる可能性がある。

Blockade of a cystine/glutamate transporter can reduce glioma-induced epilepsy in mice, reports research published online this week in Nature Medicine.

Patients with brain cancers called gliomas often have seizures due to secretion of the excitatory neurotransmitter glutamate from the tumor cells. Gliomas require the amino acid cystine to survive, and the cystine/glutamate transporter on tumor cells shuttles cystine into the tumor cell while simultaneously secreting large amounts of glutamate onto the surrounding brain tissue. This causes neurons in the tumor vicinity to become overexcitable, resulting in the development of seizures.

Harald Sontheimer and colleagues administer a Food and Drug Administration approved inhibitor of the cystine/glutamate transporter called sulfasalazine, which is currently used to treat patients with gut inflammation, to tumor-bearing mice. They show that the drug can prevent the increase in brain glutamate levels caused by the tumors, and can reduce glioma-induced epilepsy in mice. The findings therefore suggest a potential new therapeutic approach to reducing brain tumor-induced seizures in humans.

doi: 10.1038/nm.2453


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。